Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RELAY-Effusion: ramucirumab plus erlotinib in untreated EGFR-mutated NSCLC with pleural effusion
jRCTs051210138Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Dec 2021
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ramucirumab and erlotinib in non-small cell lung cancer (NSCLC) and malignant pleural effusion (MPE), sponsored by Eli Lilly and Company. Primary endpoint: Progression-free survival. Started Dec 2021; status: completed.
02
Drugs
ramucirumaberlotinib
03
Conditions
non-small cell lung cancer (NSCLC)malignant pleural effusion (MPE)
Beyond the preview
Go deeper on jRCTs051210138.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs051210138.